Amending the definition of "psilocybin" in the uniform controlled substances act to exclude the pharmaceutical composition of crystalline polymorph psilocybin and adding crystalline polymorph psilocybin to schedule IV of the uniformed controlled substance act.
Expanding the scope of practice of naturopathic doctors, specifying continuing education requirements, increasing the required amount of professional liability insurance and modifying certain provisions relating to the licensure and regulations of naturopathic doctors.
Prohibiting the transfer of hemp-derived cannabinoid products to any person under the age of 21, establishing packaging and labeling requirements for such products and amending the definition of industrial hemp and hemp products.